Shopping Cart 0
Cart Subtotal
USD 0

Amarin Corp Plc (AMRN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The company's lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription capsule used as an adjunct to diet, for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia and high triglyceride levels or mixed dyslipidemia. The company is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy. Amarin markets the product in the US through wholesalers and specialty pharmacy providers. The company has subsidiaries in Ireland, the US, Scotland and Israel. Amarin is headquartered at Dublin, Ireland.

Amarin Corp Plc (AMRN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Amarin and HLS Therapeutics Enter into Agreement 11

Amarin Enters into Development Agreement with Eddingpharm 12

Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13

Licensing Agreements 15

Amarin Enters into Licensing Agreement with Mochida Pharma 15

Equity Offering 16

Amarin Raises USD65 Million in Public Offering of American Depositary Shares 16

Amarin Files Registration Statement for Public Offering of ADS 17

Amarin Announces Underwriter's Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 18

Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 20

Amarin Completes Public Offering Of Shares For USD 121.5 Million 21

Debt Offering 23

Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23

Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24

Amarin Corporation Completes Private Placement For USD 100 Million 25

Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For USD 150 Million 26

Acquisition 27

Teva Pharma Rumored To Acquire Amarin 27

Amarin Corp Plc-Key Competitors 28

Amarin Corp Plc-Key Employees 29

Amarin Corp Plc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Nov 01, 2018: Amarin reports third quarter 2018 financial results and provides update on operations 31

Aug 01, 2018: Amarin reports second quarter 2018 financial results and provides update on operations 35

May 02, 2018: Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations 38

Feb 27, 2018: Amarin Reports Announces Fourth Quarter and Full Year 2017 Financial Results 40

Nov 01, 2017: Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations 45

Aug 02, 2017: Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations 47

May 03, 2017: Amarin reports lower Q1 net loss, re-affirms annual guidance 50

Feb 28, 2017: Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations 51

Jan 05, 2017: Amarin announces revenue forecast for 2017 54

Jan 05, 2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 56

Corporate Communications 58

Apr 23, 2018: Amarin Announces Promotes Aaron Berg To Chief Commercial Officer 58

Product News 59

06/12/2017: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides 59

05/18/2017: Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care 60

05/03/2017: Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations 61

03/16/2017: Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study 66

03/15/2017: Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology 67

01/05/2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 68

Clinical Trials 70

Sep 13, 2017: Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer 70

Aug 14, 2017: Amarin Provides Update on Vascepa 71

Other Significant Developments 73

Apr 04, 2018: Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa Promotion Initiatives 73

Appendix 75

Methodology 75

About GlobalData 75

Contact Us 75

Disclaimer 75


List Of Figure

List of Figures

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Amarin Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarin Corp Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amarin and HLS Therapeutics Enter into Agreement 11

Amarin Enters into Development Agreement with Eddingpharm 12

Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13

Amarin Enters into Licensing Agreement with Mochida Pharma 15

Amarin Raises USD65 Million in Public Offering of American Depositary Shares 16

Amarin Files Registration Statement for Public Offering of ADS 17

Amarin Announces Underwriter's Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 18

Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 20

Amarin Completes Public Offering Of Shares For USD 121.5 Million 21

Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23

Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24

Amarin Corporation Completes Private Placement For USD 100 Million 25

Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For USD 150 Million 26

Teva Pharma Rumored To Acquire Amarin 27

Amarin Corp Plc, Key Competitors 28

Amarin Corp Plc, Key Employees 29

Amarin Corp Plc, Subsidiaries 30

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Amarin Corp Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Amarin Corp Plc (Amarin) is a biopharmaceutical company which develops and commercializes medicines for cardiovascular domain. The company's lead product Vascepa (icosapent ethyl) is a US FDA approved single-molecule prescription capsule used as an adjunct to diet, for the reduction of triglyceride levels in adult patients with severe hypertriglyceridemia and high triglyceride levels or mixed dyslipidemia. The company is also evaluating Vascepa as an add-on therapy to reduce major cardiovascular events in an at-risk patient population on statin therapy. Amarin markets the product in the US through wholesalers and specialty pharmacy providers. The company has subsidiaries in Ireland, the US, Scotland and Israel. Amarin is headquartered at Dublin, Ireland.

Amarin Corp Plc (AMRN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Amarin and HLS Therapeutics Enter into Agreement 11

Amarin Enters into Development Agreement with Eddingpharm 12

Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13

Licensing Agreements 15

Amarin Enters into Licensing Agreement with Mochida Pharma 15

Equity Offering 16

Amarin Raises USD65 Million in Public Offering of American Depositary Shares 16

Amarin Files Registration Statement for Public Offering of ADS 17

Amarin Announces Underwriter's Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 18

Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 20

Amarin Completes Public Offering Of Shares For USD 121.5 Million 21

Debt Offering 23

Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23

Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24

Amarin Corporation Completes Private Placement For USD 100 Million 25

Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For USD 150 Million 26

Acquisition 27

Teva Pharma Rumored To Acquire Amarin 27

Amarin Corp Plc-Key Competitors 28

Amarin Corp Plc-Key Employees 29

Amarin Corp Plc-Locations And Subsidiaries 30

Head Office 30

Other Locations & Subsidiaries 30

Recent Developments 31

Financial Announcements 31

Nov 01, 2018: Amarin reports third quarter 2018 financial results and provides update on operations 31

Aug 01, 2018: Amarin reports second quarter 2018 financial results and provides update on operations 35

May 02, 2018: Amarin Reports First Quarter 2018 Financial Results and Provides Update on Operations 38

Feb 27, 2018: Amarin Reports Announces Fourth Quarter and Full Year 2017 Financial Results 40

Nov 01, 2017: Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations 45

Aug 02, 2017: Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations 47

May 03, 2017: Amarin reports lower Q1 net loss, re-affirms annual guidance 50

Feb 28, 2017: Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations 51

Jan 05, 2017: Amarin announces revenue forecast for 2017 54

Jan 05, 2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 56

Corporate Communications 58

Apr 23, 2018: Amarin Announces Promotes Aaron Berg To Chief Commercial Officer 58

Product News 59

06/12/2017: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides 59

05/18/2017: Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care 60

05/03/2017: Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations 61

03/16/2017: Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study 66

03/15/2017: Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology 67

01/05/2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 68

Clinical Trials 70

Sep 13, 2017: Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer 70

Aug 14, 2017: Amarin Provides Update on Vascepa 71

Other Significant Developments 73

Apr 04, 2018: Amarin Updates First Quarter Revenue Guidance, Reiterates Full Year Guidance and Updates on REDUCE-IT Cardiovascular Outcomes Study Progress and Vascepa Promotion Initiatives 73

Appendix 75

Methodology 75

About GlobalData 75

Contact Us 75

Disclaimer 75


List Of Figure

List of Figures

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Amarin Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Amarin Corp Plc, Deals By Therapy Area, 2012 to YTD 2018 9

Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Amarin and HLS Therapeutics Enter into Agreement 11

Amarin Enters into Development Agreement with Eddingpharm 12

Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13

Amarin Enters into Licensing Agreement with Mochida Pharma 15

Amarin Raises USD65 Million in Public Offering of American Depositary Shares 16

Amarin Files Registration Statement for Public Offering of ADS 17

Amarin Announces Underwriter's Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 18

Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 20

Amarin Completes Public Offering Of Shares For USD 121.5 Million 21

Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23

Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24

Amarin Corporation Completes Private Placement For USD 100 Million 25

Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For USD 150 Million 26

Teva Pharma Rumored To Acquire Amarin 27

Amarin Corp Plc, Key Competitors 28

Amarin Corp Plc, Key Employees 29

Amarin Corp Plc, Subsidiaries 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Amarin Corp Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.